Dupixent's current patent protection is set to expire in 2035 [1]. However, this expiration date is subject to change due to potential patent challenges and the creation of biosimilar versions [2].
When does Dupixent's exclusivity end?
Dupixent's market exclusivity is tied to its patent expiration, anticipated in 2035 [1]. This exclusivity prevents competitors from launching generic or biosimilar versions of the drug [2].
What happens if Dupixent's patent is challenged?
If Dupixent's patents are successfully challenged, it could lead to an earlier expiration of its market exclusivity [2]. This would allow biosimilar manufacturers to potentially enter the market sooner than 2035 [3].
Can biosimilars be approved before patent expiry?
Biosimilar versions of Dupixent cannot be approved and marketed before the expiration of its relevant patents and exclusivity periods [3]. The process for biosimilar approval involves demonstrating similarity to the reference product, but market entry is contingent on patent status [3].
Who makes Dupixent and who are its competitors?
Dupixent is manufactured by Regeneron Pharmaceuticals [4]. Key competitors in the market for atopic dermatitis, asthma, and other inflammatory conditions include drugs like Xeljanz, Rinvoq, and Cibinqo [5].
What is the legal status of Dupixent's patents?
Dupixent is protected by multiple patents [2]. These patents are crucial for maintaining the drug's market exclusivity. As with many branded pharmaceuticals, these patents can become subjects of litigation and challenges from generic and biosimilar companies [2].
How does Dupixent's patent timeline compare to other biologics?
Biologics like Dupixent typically have long patent protection periods, often extending for many years after initial approval. The 2035 expiration date for Dupixent aligns with the general trend for complex biologic drugs, which aim to recoup significant research and development investments [1][2].